Veliparib ER is a small molecule commercialized by AbbVie, with a leading Phase III program in Metastatic Breast Cancer. According to Globaldata, it is involved in 93 clinical trials, of which 72 were completed, 16 are ongoing, and 5 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Veliparib ER’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Veliparib ER is expected to reach an annual total of $157 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Veliparib ER Overview
Veliparib (ABT-888) is under development for the treatment of non- squamous non-small cell lung cancer, epithelial ovarian cancer, BRCA associated breast cancer, peritoneal cancer, fallopian tube cancer, glioblastoma multiforme, metastatic melanoma, small-cell lung cancer, testicular cancer, metastatic adenocarcinoma of the pancreas, germ cell tumors, germinomatous germ cell tumors, nongerminomatous germ cell tumors, rectal cancer, small cell lung cancer, head and neck cancer squamous cell carcinoma, oropharyngeal cancer, relapsed and refractory acute myeloid leukemia, polycythemia vera, myelofibrosis, anaplastic astrocytoma, essential thrombocythemia, chronic myelocytic leukemia, acute myelocytic leukemia, relapsed or refractory pre-B- or T-cell acute lymphoblastic leukemia (ALL), myeloproliferative disorders, diffuse large b-cell lymphoma, mantle cell lymphoma natural killer cell lymphomas and T-cell- lymphoma. It is administered oral route formulated as a capsule. It acts by targeting PARP. It is an extended release formulation.
It was also under development for solid tumor including castration resistant prostate cancer, squamous non-small cell lung cancer (NSCLC), hepatocelluar carcinoma, triple-negative breast cancer, gastric cancer, cervical cancer, metastatic melanoma, lymphoma and relapsed and/or refractory myeloma, pancreatic cancer, biliary tumor,transitional cell cancer (urothelial cell cancer),brenner tumor,endometrial cancer,clear cell squamous cell carcinoma,testicular cancer, refractory brain metastasis, HER2 positive metastatic breast cancer, esophageal cancer, HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer and prostate cancer.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
The company reported revenues of (US Dollars) US$58,054 million for the fiscal year ended December 2022 (FY2022), an increase of 3.3% over FY2021. In FY2022, the company’s operating margin was 31.2%, compared to an operating margin of 31.9% in FY2021. In FY2022, the company recorded a net margin of 20.4%, compared to a net margin of 20.5% in FY2021. The company reported revenues of US$12,225 million for the first quarter ended March 2023, a decrease of 19.2% over the previous quarter.
For a complete picture of Veliparib ER’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.